Previous 10 | Next 10 |
VACAVILLE, CA / ACCESSWIRE / July 19, 2023 / Athena Gold Corporation (OTCQB:AHNR)(CSE:ATHA) (" Athena " or the " Company ") is pleased to announce that it has successfully completed the Company's Spring 2023 reverse circulation (" RC ") drill program of nine (9) angle holes (see press release da...
New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid-ß -mediated toxicity In preclinical models, ATH-1105 protects against pathologies common to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) Data presented a...
BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that three poster presentations will be delivered ...
VACAVILLE, CA / ACCESSWIRE / June 20, 2023 / Athena Gold Corporation (OTCQB:AHNR)(CSE:ATHA) (" Athena " or the " Company ") has commenced its first 2023 RC drill program at its 100% owned Excelsior Springs Project (" Project ") located approximately 45 miles southwest of Goldfield in Esmeralda C...
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the fol...
2023-05-22 07:39:51 ET Clinical-stage biopharmaceutical company, Athira Pharma ( ATHA ) appoints Andrew Gengos as CFO and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira’s CFO for eight years. ...
BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial...
VACAVILLE, CA / ACCESSWIRE / May 15, 2023 / Athena Gold Corporation (OTCQB:AHNR)(CSE:ATHA) (" Athena " or the " Company ") is pleased to present its 2023 exploration plans at its 100% owned Excelsior Springs Project (" Project ") located approximately 45 miles southwest of Goldfield in Esmeralda...
2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...